Results for tag: "Inlyta"

Inlyta is a drug used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer. It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Inlyta is approved by the US Food and Drug Administration (FDA) for the treatment of advanced RCC in adults who have received prior anti-angiogenic therapy. It is also approved for use in combination with axitinib for the first-line treatment of advanced RCC. Inlyta is part of a larger market of kidney cancer drugs, which includes other TKIs such as sunitinib, pazopanib, and cabozantinib, as well as immunotherapies such as nivolumab and ipilimumab. These drugs are used to treat different stages of kidney cancer, from early-stage to advanced. The companies in the Inlyta market include Pfizer, Novartis, Bristol-Myers Squibb, Merck, and AstraZeneca. Show Less Read more